Atsena raises $150M to target rare form of blindness with gene therapy
There's still money to be raised by gene therapy startups with good clinical data. On Wednesday, North Carolina biotech Atsena Therapeutics said it had raised a $150 million Series C to try and be the ...
There's still money to be raised by gene therapy startups with good clinical data.
On Wednesday, North Carolina biotech Atsena Therapeutics said it had raised a $150 million Series C to try and be the ...
